Farxiga approved in the US for the treatment of paediatric type-2 diabetes

Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date

Lyndra Therapeutics raises US$101 million in Series E funding

Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners

New products and nutraceuticals added under Jan Aushadhi Pariyojana

The product basket increased to 1800 medicines and 285 Surgical Equipment

Farxiga’s expanded approval highlights potential to differentiate in HF space, says GlobalData

Farxiga is expected to have such a strong influence on the market due to the impressive results

Glenmark launches Triple FDC of Teneligliptin with Pioglitazone and Metformin for adults with Type 2 Diabetes

This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation

Glenmark launches Zita D for adults with Type 2 diabetes having comorbidities

A well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities

Bayer chronic kidney disease medication Kerendia can gain quick market penetration in India, says GlobalData

Glenmark launches Sitagliptin and its FDC at affordable price

These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens

Daewoong completes combination therapy of antidiabetic drug Enavogliflozin

Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy

WHO new Essential Medicines Lists focus on diabetes and cancer

The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all